tbuckley/cabot-search huggingface dataset:
Abstract 9435: An Ultrasound Image of Spleen Shear Wave Elastography Predicts Adverse Outcomes in Heart Failure Patients
Authors: Tomofumi Misaka, Akiomi Yoshihisa, Yasuhiro Ichijo, Yukiko Sugawara, Himika Ohara, Yu Hotsuki, Koichiro Watanabe, Yu Sato, Masayoshi Oikawa, ATSUSHI KOBAYASHI, Yasuchika Takeishi
Journal: Circulation (2021)

Introduction: Cardiac and multiple organ network is involved in the pathophysiology of heart failure (HF). Ultrasound shear wave elastography (SWE) is a novel non-invasive imaging that is capable of quantitatively and directly estimating tissue stiffness, but its significance of the spleen has not been fully investigated, and the interactions between the heart and the spleen are poorly understood. This study aimed to clarify the clinical relevance of the spleen in HF patients by splenic ultrasonographic evaluation. Methods and Results: We applied the two-dimensional SWE of the spleen in consecutive hospitalized 232 patients with HF. We also measured spleen shear wave dispersion (SWD) to evaluate the tissue viscosity as well as the spleen index to assess the splenic size. In comparison to non-HF patients (n = 35), spleen SWE and SWD were significantly increased in HF patients (2.18 ± 0.28 vs. 2.38 ± 0.54 m/s, P = 0.03 and 11.3 ± 3.4 vs. 13.9 ± 5.3 m/s, P &lt; 0.01, respectively) but spleen index did not differ between the two groups (24.1 ± 8.2 vs. 24.4 ± 9.8, P = NS). In HF patients, spleen SWE was negatively correlated with right ventricular fractional area change (P = 0.01) and positively correlated with the 7S domain of collagen type IV, a marker of fibrosis (P = 0.01). During a mean follow-up period of 303 days, the Kaplan-Meier analysis demonstrated that a higher spleen SWE was associated with a lower cardiac event-free rate from cardiac deaths and decompensated heart failure ( Figure ), but spleen SWD or spleen index was not. A multivariable Cox proportional hazard analysis revealed that spleen SWE was an independent predictor for the cardiac events (hazard ratio 3.4, P &lt; 0.01). Conclusion: Among the splenic ultrasonographic parameters, spleen SWE was strongly associated with adverse outcomes in HF patients accompanied by organ fibrosis and right ventricular dysfunction.
Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Sham Mailankody, Claudia Diamonte, Lisa Fitzgerald, Peter Kane, Xiuyan Wang, Devanjan S. Sikder, Brigitte Senechal, Vladimir P. Bermudez, Diana Frias, Justina Morgan, Patrick Grant, Terence J Purdon, Kinga Hosszu, Sean M Devlin, Urvi A Shah, Jonathan Landa, Alexander Lesokhin, Neha Korde, Hani Hassoun, Carlyn Tan, Malin Hultcrantz, Gunjan L. Shah, Heather J Landau, David J. Chung, Michael Scordo, Mikhail Roshal, Ola Landgren, Ahmet Dogan, Sergio A Giralt, Jae H Park, Isabelle Rivière, Renier J Brentjens, Eric L Smith
Journal: Blood (2021)
TP53 Alterations Enrich in Ezb/C3-like Subclassified Relapsed or Refractory DLBCL and Are Susceptible to BRD4 Protac Inhibition
Authors: Shelby Lund, Valentine Ngisa, Zoe Rivard, Jinda Guidinger, Kennedee Weber, Keenan T. Hartert
Journal: Blood (2021)
Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study
Authors: Joachim Baech, Marianne Tang Severinsen, Andreas Kiesbye Øvlisen, Henrik Frederiksen, Peter Vestergaard, Christian Torp-Pedersen, Judit M. Jørgensen, Michael Roost Clausen, Christian Bjørn Poulsen, Peter de Nully Brown, Anne Ortved Gang, Robert Schou Pedersen, Karin Ekstroem Smedby, Sandra Eloranta, Lasse H. Jakobsen, Tarec Christoffer El-Galaly
Journal: Blood (2021)
Abstract 9078: The Bad Bleeding Score: A Simple Score to Assess Bleeding Risk in Atrial Fibrillation Patients With Direct Oral Anticoagulants
Authors: Masato Kawasaki, Takahisa Yamada, Tetsuya Watanabe, Takashi Morita, Atsushi Kikuchi, Masahiro Seo, Jun Nakamura, Kiyomi Kayama, Daisuke Sakamoto, Kunpei Ueda, Takehiro Kougame, Yuto Tamura, Takeshi Fujita, Keisuke Nishigaki, Yuki Kokubu, Yuto Fukuda, Masatake Fukunami
Journal: Circulation (2021)

Backgrounds: Therapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations. Methods and Results: We retrospectively studied 924 AF patients who were prescribed with direct oral anticoagulants (DOAC) in a single center cohort between May 2011 and July 2015. Using Cox proportional hazards regression, 3 factors were identified to be associated with bleeding among those patients over 1.9 year-follow up. The predictive performance of 3-item score (BAD score: the sum of the point values of the following parameters; bleeding history, age (≥75yrs) and dual antiplatelet therapy) and 3 existing risk scores (HAS-BLED, ORBIT, and ATRIA) were then assessed in the sequel cohort between Aug 2015 and Jun 2016. BAD score had good ability to identify those who bled in an external validation population (C-index: BAD score, 0.63; HAS-BLED, 0.61; ORBIT, 0.64; ATRIA, 0.59). The risk of bleeding increased with higher BAD score. Conclusions: BAD score might be a useful and simple bleeding risk score in AF patients with DOAC.
Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant <i>IDH2</i> (m <i>IDH2</i>) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)
Authors: Courtney D. DiNardo, Hartmut Dohner, Amer M. Zeidan, Andre C. Schuh, Paresh Vyas, Eytan M. Stein, Andrew H. Wei, Stephane de Botton, Clara Chen, Jennifer Lord-Bessen, Patricia Martin-Regueira, Frederik Lersch, Jing Gong, Shien Guo, Ling Shi, Pau Montesinos
Journal: Blood (2021)
Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase Deficiency
Authors: Eduard J. Van Beers, Hanny Al-Samkari, Rachael F. Grace, Wilma Barcellini, Andreas Glenthoej, Malia P. Judge, Penelope A. Kosinski, Emily Xu, Vanessa Beynon, Bryan McGee, John B. Porter, Kevin H.M. Kuo
Journal: Blood (2021)
Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Genomic and Molecular Markers for Decitabine (DAC) Plus Valproic-Acid (VPA) Treatment Response in Patients with Myelodysplastic Syndromes (MDS)
Authors: Michael Castro, Ansu Kumar, Himanshu Grover, Vivek Patil, Shweta Kapoor, Ashish Kumar Agrawal, Mohammed Sauban, Samiksha Avinash Prasad, Kabya Basu, Rakhi Purushothaman Suseela, Chandan Kumar, Prashant Ramachandran Nair, Pallavi Kumari, Anusha Pampana, Yashaswini S Ullal, Humera Azam, Nagendra Prasad, Anish Raju R Amara, Diwyanshu Sahu, Nithya T Raveendaran, Archana Palillam Veedu, Nirjhar Mundkur, Sanjana Patel, James Christie, Michele Dundas Macpherson, Scott C Howard
Journal: Blood (2021)
Mitochondrial complex I as a therapeutic target for Alzheimer's disease
Authors: Eugenia Trushina, Sergey Trushin, Md Fayad Hasan
Journal: Acta Pharmaceutica Sinica B (2021)

Alzheimer's disease (AD), the most prominent form of dementia in the elderly, has no cure. Strategies focused on the reduction of amyloid beta or hyperphosphorylated Tau protein have largely failed in clinical trials. Novel therapeutic targets and strategies are urgently needed. Emerging data suggest that in response to environmental stress, mitochondria initiate an integrated stress response (ISR) shown to be beneficial for healthy aging and neuroprotection. Here, we review data that implicate mitochondrial electron transport complexes involved in oxidative phosphorylation as a hub for small molecule-targeted therapeutics that could induce beneficial mitochondrial ISR. Specifically, partial inhibition of mitochondrial complex I has been exploited as a novel strategy for multiple human conditions, including AD, with several small molecules being tested in clinical trials. We discuss current understanding of the molecular mechanisms involved in this counterintuitive approach. Since this strategy has also been shown to enhance health and life span, the development of safe and efficacious complex I inhibitors could promote healthy aging, delaying the onset of age-related neurodegenerative diseases.
Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect ® Multiple Myeloma (MM) Disease Registry
Authors: Derek Tang, Parameswaran Hari, Karthik Ramasamy, Katja Weisel, Prashant Joshi, Liang Liu, Min Che, Gabriela Hernandez, Rafat Abonour, James W. Hardin, Robert M. Rifkin, Sikander Ailawadhi, Hans C. Lee, Howard R. Terebelo, Brian G.M. Durie, Mohit Narang, Kathleen Toomey, Cristina Gasparetto, Lynne I. Wagner, Sundar Jagannath
Journal: Blood (2021)
Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillance
Authors: Emma Pritchard, Joel Jones, Karina-Doris Vihta, Nicole Stoesser, Prof Philippa C. Matthews, David W. Eyre, Thomas House, John I Bell, Prof John N Newton, Jeremy Farrar, Prof Derrick Crook, Susan Hopkins, Duncan Cook, Emma Rourke, Ruth Studley, Prof Ian Diamond, Prof Tim Peto, Koen B. Pouwels, Prof A. Sarah Walker
Journal: The Lancet Regional Health - Europe (2021)

The COVID-19 pandemic is rapidly evolving, with emerging variants and fluctuating control policies. Real-time population screening and identification of groups in whom positivity is highest could help monitor spread and inform public health messaging and strategy.
Worsening renal function in acute heart failure in the context of diuretic response
Authors: Johanna E. Emmens, Jozine M. ter Maaten, Yuya Matsue, Sylwia M. Figarska, Iziah E. Sama, Gad Cotter, John G.F. Cleland, Beth A. Davison, G. Michael Felker, Michael M. Givertz, Barry Greenberg, Peter S. Pang, Thomas Severin, Claudio Gimpelewicz, Marco Metra, Adriaan A. Voors, John R. Teerlink
Journal: European Journal of Heart Failure (2021)
Chromatin spatial organization of wild type and mutant peanuts reveals high-resolution genomic architecture and interaction alterations
Authors: Xingguo Zhang, Manish K. Pandey, Jianping Wang, Kunkun Zhao, Xingli Ma, Zhongfeng Li, Kai Zhao, Fangping Gong, Baozhu Guo, Rajeev K. Varshney, Dongmei Yin
Journal: Genome biology (2021)

Abstract Background Three-dimensional (3D) chromatin organization provides a critical foundation to investigate gene expression regulation and cellular homeostasis. Results Here, we present the first 3D genome architecture maps in wild type and mutant allotetraploid peanut lines, which illustrate A/B compartments, topologically associated domains (TADs), and widespread chromatin interactions. Most peanut chromosomal arms (52.3%) have active regions (A compartments) with relatively high gene density and high transcriptional levels. About 2.0% of chromosomal regions switch from inactive to active (B-to-A) in the mutant line, harboring 58 differentially expressed genes enriched in flavonoid biosynthesis and circadian rhythm functions. The mutant peanut line shows a higher number of genome-wide cis-interactions than its wild-type. The present study reveals a new TAD in the mutant line that generates different chromatin loops and harbors a specific upstream AP2EREBP -binding motif which might upregulate the expression of the GA2ox gene and decrease active gibberellin (GA) content, presumably making the mutant plant dwarf. Conclusions Our findings will shed new light on the relationship between 3D chromatin architecture and transcriptional regulation in plants.
Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment
Authors: Stephanie J. Lee, Mukta Arora, Zachariah Defilipp, Mohammad Issam Abu Zaid, Antonio Di Stasi, Vedran Radojcic, Michael L. Meyers, Hope Qamoos, Peter Ordentlich, Christine Quaranto, Aaron Schmitt, Yu Gu, Amandeep Salhotra, Iskra Pusic, Carrie Lynn Kitko
Journal: Blood (2021)
An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia
Authors: Chong Chyn Chua, John Reynolds, Anoop Kumar Enjeti, Devendra Hiwase, Paula Marlton, Ashish Bajel, Shuh Ying Tan, Edward S. Morris, Chun-Kei-Kris Ma, Carolyn Grove, Julian Cooney, Ashanka Beligaswatte, Natasha Anstee, Stephen B Ting, Travis Perera, Amanda Johnston, David Ritchie, Andrew H. Wei
Journal: Blood (2021)
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
Authors: Kirit Singh, Kelly M Hotchkiss, Aditya A Mohan, Jessica L Reedy, John H Sampson, Mustafa Khasraw
Journal: Journal for ImmunoTherapy of Cancer (2021)

Glioblastoma is the the most common primary brain tumor in adults. Onset of disease is followed by a uniformly lethal prognosis and dismal overall survival. While immunotherapies have revolutionized treatment in other difficult-to-treat cancers, these have failed to demonstrate significant clinical benefit in patients with glioblastoma. Obstacles to success include the heterogeneous tumor microenvironment (TME), the immune-privileged intracranial space, the blood–brain barrier (BBB) and local and systemic immunosuppressions. Monoclonal antibody-based therapies have failed at least in part due to their inability to access the intracranial compartment. Bispecific T-cell engagers are promising antibody fragment-based therapies which can bring T cells close to their target and capture them with a high binding affinity. They can redirect the entire repertoire of T cells against tumor, independent of T-cell receptor specificity. However, the multiple challenges posed by the TME, immune privilege and the BBB suggest that a single agent approach may be insufficient to yield durable, long-lasting antitumor efficacy. In this review, we discuss the mechanism of action of T-cell engagers, their preclinical and clinical developments to date. We also draw comparisons with other classes of multispecific antibodies and potential combinations using these antibody fragment therapies.
Platelet-Rich Plasma Injection vs Sham Injection and Tendon Dysfunction in Patients With Chronic Midportion Achilles Tendinopathy
Authors: Vincent Gremeaux, Eric Noël, Jean-Francois Kaux
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients
Authors: Laurent Garderet, Frédérique Kuhnowski, Benoit Berge, Murielle Roussel, Martine Escoffre-Barbe, Ingrid Lafon, Thierry Facon, Xavier Leleu, Lionel Karlin, Aurore Perrot, Philippe Moreau, Gerald Marit, Anne-Marie Stoppa, Bruno Royer, Carine Chaleteix, Mourad Tiab, Carla Araujo, Pascal Lenain, Margaret Macro, Eric G. Voog, Lotfi Benboubker, Olivier Thierry Allangba, Eric Jourdan, Frédérique Orsini-Piocelle, Sabine Brechignac, Jean-Richard Eveillard, Karim Belhadj, Marc Wetterwald, Brigitte Pegourie, Arnaud Jaccard, Jean Claude Eisenmann, Sylvie Glaisner, Mohamad Mohty, Cyrille Hulin, Herve Avet Loiseau, Claire Mathiot, Michel Attal
Journal: Blood (2021)
Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi-Cel) Treatment
Authors: Joseph Maakaron, Emily Stene, Megan Bruns, Todd E. DeFor, Najla H El Jurdi, Veronika Bachanova, Daniel J. Weisdorf, Jeffrey S. Miller, Murali Janakiram, Mark Juckett
Journal: Blood (2021)
CNTM-02. Regulation of glioma-network integration by tumor mediated secretion of TSP-1
Authors: Mikias Negussie, Saritha Krishna, Shawn Hervey-Jumper
Journal: Neuro-Oncology (2021)

Abstract Glioma exists in the complex neural circuitry of the brain, making the interface between neoplastic and healthy neurons and glia potentially damaging to long range neural networks and stimulatory to tumor growth. Thrombospondin-1 (TSP-1), an astrocyte derived neurogenic factor expressed by glia of the normal brain, has been found to be upregulated in intratumoral regions with high network functional connectivity (HFC). This modified cell signaling represents cancer cell hijacking of normal physiology with direct impact on tumor biology. There is emerging evidence that neuronal activity influences glioma proliferation and gliomas promote neuronal hyperexcitability. In humans, we have recently shown that bidirectional cellular interactions between gliomas and neurons alter cognitive circuit dynamics and ultimately patient survival. Previously, a subpopulation of human high-grade glioma cells which are enriched for tumor cells with synaptogenic potential were identified (HFC-IHDwtGBM). We plan to study the mechanisms of TSP1 signaling in three different established glioma models (1) HFC-IDHwtGBM hippocampal neuron co-culture, (2) HFC-IDHwtGBM + induced neuron organoids, (3) patient derived xenografts (PDX) for in vivo GCaMP calcium imaging. This project aims to test the hypothesis that increased TSP-1 secretion from HFC-IHDwtGBM cells plays a central role in the maintenance of an invasive and proliferative tumor phenotype when compared with LFC-IHDwtGBM PDX. We hope our study guides future work focused on preventing the infiltration of tumor cells into healthy brain tissues.
Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis
Authors: Peter Dreger, Maria-Luisa Schubert, Udo Holtick, Marion Subklewe, von Tresckow Bastian, Francis A. Ayuk, Eva Maria Wagner, Gerald Wulf, Reinhard Marks, Olaf Penack, Ulf Schnetzke, Christian Koenecke, Malte Von Bonin, Matthias Stelljes, Bertram Glass, Claudia D. Baldus, Vladan Vucinic, Dimitrios Mougiakakos, Max Topp, Daniel Wolff, Roland Schroers, Peter Borchmann, Kai Rejeski, Christine Hanoun, Claudia Lengerke, Simone Thomas, Dietrich W. Beelen, Nicolaus Kröger, Wolfgang A Bethge
Journal: Blood (2021)
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥ 1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis
Authors: Brandon J. Blue, Ruta Brazauskas, Karen Chen, Shahrukh Hashmi, Leslie E. Lehmann, William A. Wood, Navneet S. Majhail, Wael Saber
Journal: Blood (2021)
Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody
Authors: Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Hironori Sakai, Wataru Hojo, Marika Watanabe, Miki Saeki, Yuri Hirakawa, Rina Sakai, Sakuya Matsumoto, Yu Mizutani, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Yamamoto Katsuya, Mitsuhiro Ito, Meiko Nishimura, Yoshinori Imamura, Naomi Kiyota, Hiroshi Matsuoka, Yasuko Mori, Hironobu Minami
Journal: Blood (2021)
Umbilical Cord Blood Transplantation after Graft Failure from a Previous Hematopoietic Stem Cell Transplantation
Authors: Fernanda Volt, Annalisa Ruggeri, Graziana Maria Scigliuolo, Regis Peffault De Latour, Marc Bierings, Amal Al-Seraihy, Henrique Bittencourt, Helene Labussiere-Wallet, Vanderson Rocha, Chantal Kenzey, Barbara Cappelli, Hanadi Rafii, Eliane Gluckman, Renato Luiz Guerino-Cunha
Journal: Blood (2021)
Abstract 9334: Clonal Hematopoiesis is Associated With Incident Severe Aortic Stenosis
Authors: Michael A Raddatz, Alexander J Silver, Eric Farber-Eger, Yaomin Xu, Quinn S Wells, Michael R Savona, Brian R Lindman, Alexander G Bick
Journal: Circulation (2021)

Introduction: Clonal hematopoiesis of indeterminate potential (CHIP) has been linked to increased risk of cardiovascular disease, mediated in part through inflammation. Like CHIP, aortic stenosis (AS) has a strong association with aging and involves pathologic inflammation. A prior study found that AS patients with CHIP have worse outcomes (Mas-Peiro, Eur Heart J , 2020); however, whether CHIP is associated with incident AS is presently unknown. Methods: We tested the association of CHIP and incident severe AS by echocardiography (defined by aortic valve area (AVA) ≤ 1 cm 2 or aortic valve peak jet velocity (V max ) ≥ 4 m/s) in 6,866 patients over 40 years of age in the Vanderbilt University Medical Center BioVU repository. Analyses were performed using Cox proportional hazards models adjusted for age, sex, self-reported race, ethnicity, type 2 diabetes, hypertension, and hyperlipidemia. Results: CHIP mutations were identified in 3.5% of patients (n = 241 of 6,866 patients; DNMT3A , n = 97; JAK2 , n = 48; TET2 , n = 41; ASXL1 , n = 33; mutations in multiple genes, n = 22). Severe AS by V max and AVA was seen in 2.7% (180/6,732) and 8.8% (359/4,088) of patients, respectively. Patients with CHIP mutations were older (63.9y vs 61.9y; P = 5.8 x 10 -3 ) and more often white (93.8% vs 87.5%; P = 5.1 x 10 -3 ). Presence of CHIP mutation was associated with increased risk of incident severe AS by V max (hazard ratio [HR] = 1.82 [1.03-3.20]; P = 0.039, Figure ) and AVA (HR = 1.65 [1.07-2.54]; P = 0.023). DNMT3A mutations, specifically, were associated with incident severe AS (V max : HR = 2.42 [1.013-5.18]; P = 0.022; AVA: HR = 2.27 [1.27-4.05]; P = 5.4 x 10 -3 ). Conclusions: We found that the presence of a CHIP mutation is associated with an increased risk of incident severe AS. This finding underscores the need for preventative cardiovascular care for patients with CHIP and suggests a role for immunobiology in AS pathophysiology.
CD271 antibody-functionalized microspheres capable of selective recruitment of reparative endogenous stem cells for in situ bone regeneration
Authors: Han Sun, Qianping Guo, Chen Shi, Ross H. McWilliam, Jianquan Chen, Caihong Zhu, Fengxuan Han, Pinghui Zhou, Huilin Yang, Jinbo Liu, Xiaoliang Sun, Bin Meng, Wenmiao Shu, Bin Li
Journal: Biomaterials (2021)
Frontline Therapy with Bendamustine-Rituximab (BR) in Patients with Treatment-Naïve Waldenstrom's Macroglobulinemia Confers Similar Long-Term Outcomes to R-CVP in a Real-World Setting: A Population-Based Analysis
Authors: Jowon Laura Kim, Alina S. Gerrie, Kerry J. Savage, Diego Villa, David W. Scott, Jeffrey W Craig, Pedro Farinha, Brian Skinnider, Graham W. Slack, Joseph M. Connors, Laurie H. Sehn, Ciara L. Freeman
Journal: Blood (2021)